Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031031837> ?p ?o ?g. }
- W3031031837 endingPage "3470" @default.
- W3031031837 startingPage "3464" @default.
- W3031031837 abstract "Background Regorafenib is an oral multikinase inhibitor targeting angiogenesis, oncogenesis, and cancer proliferation/metastasis. This study evaluated the efficacy of regorafenib in refractory biliary tract cancer (BTC) in a multi‐institutional phase 2 study. Methods Patients with BTC who progressed on at least 1 line of systemic therapy received regorafenib at 160 mg daily for 21 days on and 7 days off. The primary endpoint was 6‐month overall survival (OS), and the secondary endpoints were median OS, progression‐free survival (PFS), and objective response rates. Pretreatment plasma was collected for cytokine evaluation. Results A total of 39 patients were enrolled, and 33 were evaluable for efficacy. The median PFS and OS were 3.7 and 5.4 months, respectively, with survival rates of 46.2% at 6 months, 35.9% at 12 months, and 25.6% at 18 months for the intention‐to‐treat population. For the 33 evaluable patients who received regorafenib for at least 3 weeks, the median PFS and OS were 3.9 and 6.7 months, respectively, with survival rates of 51.5% at 6 months, 39.4% at 12 months, and 27.3% at 18 months. The objective response rate was 9.1%, and the disease control rate was 63.6%. Twenty‐eight patients (71.8%) experienced grade 3/4 adverse events. Among the 23 cytokines analyzed, elevated baseline vascular endothelial growth factor D (VEGF‐D) was associated with shorter PFS, whereas elevated baseline interleukin 6 (IL‐6) and glycoprotein 130 (GP130) were associated with shorter OS. Conclusions Regorafenib demonstrated modest clinical efficacy in heavily pretreated patients with BTC. Further exploration of biomarkers is warranted to identify a group of patients with BTC who may benefit from regorafenib." @default.
- W3031031837 created "2020-06-05" @default.
- W3031031837 creator A5009314752 @default.
- W3031031837 creator A5031878697 @default.
- W3031031837 creator A5037380551 @default.
- W3031031837 creator A5044586794 @default.
- W3031031837 creator A5045482037 @default.
- W3031031837 creator A5054848065 @default.
- W3031031837 creator A5065100210 @default.
- W3031031837 creator A5080982053 @default.
- W3031031837 creator A5085949674 @default.
- W3031031837 date "2020-05-26" @default.
- W3031031837 modified "2023-10-14" @default.
- W3031031837 title "A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer" @default.
- W3031031837 cites W1968209756 @default.
- W3031031837 cites W1985335252 @default.
- W3031031837 cites W2007553857 @default.
- W3031031837 cites W2011855885 @default.
- W3031031837 cites W2028700227 @default.
- W3031031837 cites W2063515380 @default.
- W3031031837 cites W2072564984 @default.
- W3031031837 cites W2075957912 @default.
- W3031031837 cites W2095046027 @default.
- W3031031837 cites W2108215899 @default.
- W3031031837 cites W2108756633 @default.
- W3031031837 cites W2111851685 @default.
- W3031031837 cites W2113058482 @default.
- W3031031837 cites W2115261608 @default.
- W3031031837 cites W2116922255 @default.
- W3031031837 cites W2117674153 @default.
- W3031031837 cites W2146412564 @default.
- W3031031837 cites W2147834058 @default.
- W3031031837 cites W2321791130 @default.
- W3031031837 cites W2520639290 @default.
- W3031031837 cites W2560499218 @default.
- W3031031837 cites W2588040452 @default.
- W3031031837 cites W2589417649 @default.
- W3031031837 cites W2799924395 @default.
- W3031031837 cites W2858223152 @default.
- W3031031837 cites W2883599510 @default.
- W3031031837 cites W2903993960 @default.
- W3031031837 cites W2905648140 @default.
- W3031031837 cites W2913483277 @default.
- W3031031837 cites W2947109943 @default.
- W3031031837 cites W2954373381 @default.
- W3031031837 doi "https://doi.org/10.1002/cncr.32964" @default.
- W3031031837 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7787270" @default.
- W3031031837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32453456" @default.
- W3031031837 hasPublicationYear "2020" @default.
- W3031031837 type Work @default.
- W3031031837 sameAs 3031031837 @default.
- W3031031837 citedByCount "19" @default.
- W3031031837 countsByYear W30310318372020 @default.
- W3031031837 countsByYear W30310318372021 @default.
- W3031031837 countsByYear W30310318372022 @default.
- W3031031837 countsByYear W30310318372023 @default.
- W3031031837 crossrefType "journal-article" @default.
- W3031031837 hasAuthorship W3031031837A5009314752 @default.
- W3031031837 hasAuthorship W3031031837A5031878697 @default.
- W3031031837 hasAuthorship W3031031837A5037380551 @default.
- W3031031837 hasAuthorship W3031031837A5044586794 @default.
- W3031031837 hasAuthorship W3031031837A5045482037 @default.
- W3031031837 hasAuthorship W3031031837A5054848065 @default.
- W3031031837 hasAuthorship W3031031837A5065100210 @default.
- W3031031837 hasAuthorship W3031031837A5080982053 @default.
- W3031031837 hasAuthorship W3031031837A5085949674 @default.
- W3031031837 hasBestOaLocation W30310318371 @default.
- W3031031837 hasConcept C121332964 @default.
- W3031031837 hasConcept C121608353 @default.
- W3031031837 hasConcept C126322002 @default.
- W3031031837 hasConcept C141071460 @default.
- W3031031837 hasConcept C142424586 @default.
- W3031031837 hasConcept C143998085 @default.
- W3031031837 hasConcept C167734588 @default.
- W3031031837 hasConcept C197934379 @default.
- W3031031837 hasConcept C203092338 @default.
- W3031031837 hasConcept C2776248978 @default.
- W3031031837 hasConcept C2776694085 @default.
- W3031031837 hasConcept C2777025900 @default.
- W3031031837 hasConcept C2777802072 @default.
- W3031031837 hasConcept C2780739268 @default.
- W3031031837 hasConcept C2908647359 @default.
- W3031031837 hasConcept C31760486 @default.
- W3031031837 hasConcept C526805850 @default.
- W3031031837 hasConcept C535046627 @default.
- W3031031837 hasConcept C71924100 @default.
- W3031031837 hasConcept C87355193 @default.
- W3031031837 hasConcept C90924648 @default.
- W3031031837 hasConcept C99454951 @default.
- W3031031837 hasConceptScore W3031031837C121332964 @default.
- W3031031837 hasConceptScore W3031031837C121608353 @default.
- W3031031837 hasConceptScore W3031031837C126322002 @default.
- W3031031837 hasConceptScore W3031031837C141071460 @default.
- W3031031837 hasConceptScore W3031031837C142424586 @default.
- W3031031837 hasConceptScore W3031031837C143998085 @default.
- W3031031837 hasConceptScore W3031031837C167734588 @default.
- W3031031837 hasConceptScore W3031031837C197934379 @default.
- W3031031837 hasConceptScore W3031031837C203092338 @default.